{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:41:28Z","timestamp":1790023288898,"version":"4.0.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1245\/s10434-024-16142-7","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T17:02:27Z","timestamp":1725555747000},"page":"8549-8559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Survival Outcomes of Cytoreductive Surgery with HIPEC in Gastric Adenocarcinoma: A National Cancer Database Study"],"prefix":"10.1245","volume":"31","author":[{"given":"Andrii","family":"Khomiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumaya","family":"Ghaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Rodriguez Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis A.","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliott J.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Cumbler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"McCarter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Gleisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ahrendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Del Chiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Schulick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetto","family":"Mungo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"16142_CR1","unstructured":"Group UCSW. United States Cancer Statistics Data Visualizations Tool. Retrieved 5 January 2024 at https:\/\/gis.cdc.gov\/Cancer\/USCS\/#\/AtAGlance\/."},{"key":"16142_CR2","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","volume":"29","author":"WJ Yang","year":"2023","unstructured":"Yang WJ, Zhao HP, Yu Y, et al. Updates on global epidemiology, risk, and prognostic factors of gastric cancer. World J Gastroenterol. 2023;29:2452\u201368. https:\/\/doi.org\/10.3748\/wjg.v29.i16.2452.","journal-title":"World J Gastroenterol."},{"key":"16142_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3322\/caac.21749","volume":"73","author":"JM Foster","year":"2023","unstructured":"Foster JM, Zhang C, Rehman S, Sharma P, Alexander HR. The contemporary management of peritoneal metastasis: a journey from the cold past of treatment futility to a warm present and a bright future. CA Cancer J Clin. 2023;73:49\u201371. https:\/\/doi.org\/10.3322\/caac.21749.","journal-title":"CA Cancer J Clin."},{"key":"16142_CR4","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival, and risk factors. Int J Cancer. 2014;134:622\u20138. https:\/\/doi.org\/10.1002\/ijc.28373.","journal-title":"Int J Cancer."},{"key":"16142_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13045-017-0517-9","volume":"10","author":"B Badgwell","year":"2017","unstructured":"Badgwell B, Das P, Ajani J. Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. J Hematol Oncol. 2017;10:149. https:\/\/doi.org\/10.1186\/s13045-017-0517-9.","journal-title":"J Hematol Oncol."},{"key":"16142_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00000658-199703000-00004","volume":"225","author":"EC Burke","year":"1997","unstructured":"Burke EC, Karpeh MS, Conlon KC, Brennan MF. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg. 1997;225:262\u20137. https:\/\/doi.org\/10.1097\/00000658-199703000-00004.","journal-title":"Ann Surg."},{"key":"16142_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","volume":"40","author":"F Coccolini","year":"2014","unstructured":"Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapy in advanced gastric cancer: meta-analysis of randomized trials. EJSO Eur J Surg Oncol. 2014;40:12\u201326. https:\/\/doi.org\/10.1016\/j.ejso.2013.10.019.","journal-title":"EJSO Eur J Surg Oncol."},{"key":"16142_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/148420","volume":"2012","author":"Y Yonemura","year":"2012","unstructured":"Yonemura Y, Elnemr A, Endou Y, et al. Effects of neoadjuvant intraperitoneal\/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol. 2012;2012:148420. https:\/\/doi.org\/10.1155\/2012\/148420.","journal-title":"Int J Surg Oncol."},{"key":"16142_CR9","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/1097-0142(19911001)68:7<1501::aid-cncr2820680706>3.0.co;2-l","volume":"68","author":"JA Ajani","year":"1991","unstructured":"Ajani JA, Ota DM, Jessup JM, et al. Resectable gastric carcinoma: an evaluation of preoperative and postoperative chemotherapy. Cancer. 1991;68:1501\u20136. https:\/\/doi.org\/10.1002\/1097-0142(19911001)68:7%3c1501::aid-cncr2820680706%3e3.0.co;2-l.","journal-title":"Cancer."},{"key":"16142_CR10","unstructured":"Network NCC. Gastric Cancer (v.2.2023). Updated 29 August 2023. Retrieved 5 January 2024 at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf."},{"key":"16142_CR11","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol."},{"key":"16142_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/s1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang HK, Mizusawa J, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309\u201318. https:\/\/doi.org\/10.1016\/s1470-2045(15)00553-7.","journal-title":"Lancet Oncol."},{"key":"16142_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o","volume":"88","author":"B Sadeghi","year":"2000","unstructured":"Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358\u201363. https:\/\/doi.org\/10.1002\/(sici)1097-0142(20000115)88:2%3c358::aid-cncr16%3e3.0.co;2-o.","journal-title":"Cancer."},{"key":"16142_CR14","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1245\/s10434-016-5306-0","volume":"23","author":"T Boerner","year":"2016","unstructured":"Boerner T, Graichen A, Jeiter T, et al. CRS-HIPEC prolongs survival but is not curative for patients with peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23:3972\u20137. https:\/\/doi.org\/10.1245\/s10434-016-5306-0.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR15","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1245\/s10434-007-9487-4","volume":"14","author":"TD Yan","year":"2007","unstructured":"Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14:2702\u201313. https:\/\/doi.org\/10.1245\/s10434-007-9487-4.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00423-023-03163-1","volume":"408","author":"F Santullo","year":"2023","unstructured":"Santullo F, Ferracci F, Abatini C, et al. Gastric cancer with peritoneal metastases: a single-center outline and comparison of different surgical and intraperitoneal treatments. Langenbecks Arch Surg. 2023;408:437. https:\/\/doi.org\/10.1007\/s00423-023-03163-1.","journal-title":"Langenbecks Arch Surg."},{"key":"16142_CR17","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","volume":"17","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370\u20137. https:\/\/doi.org\/10.1245\/s10434-010-1039-7.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR18","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1002\/cncr.25356","volume":"116","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116:5608\u201318. https:\/\/doi.org\/10.1002\/cncr.25356.","journal-title":"Cancer."},{"key":"16142_CR19","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/jco.18.01688","volume":"37","author":"PE Bonnot","year":"2019","unstructured":"Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37:2028\u201340. https:\/\/doi.org\/10.1200\/jco.18.01688.","journal-title":"J Clin Oncol."},{"key":"16142_CR20","doi-asserted-by":"publisher","first-page":"9060","DOI":"10.1245\/s10434-021-10157-0","volume":"28","author":"L Marano","year":"2021","unstructured":"Marano L, Marrelli D, Sammartino P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with synchronous peritoneal metastases: multicenter study of \u201cItalian peritoneal surface malignancies oncoteam-S.I.C.O.\u201d Ann Surg Oncol. 2021;28:9060\u201370. https:\/\/doi.org\/10.1245\/s10434-021-10157-0.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000528609","volume":"101","author":"S Akturk Esen","year":"2023","unstructured":"Akturk Esen S, Ozgun YM, Hasturk D, et al. Neoadjuvant chemotherapy followed by cytoreductive surgery and HIPEC improves survival in peritoneal metastatic gastric cancer. Oncology. 2023;101:321\u20137. https:\/\/doi.org\/10.1159\/000528609.","journal-title":"Oncology."},{"key":"16142_CR22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/jco.22.02867","volume":"42","author":"B Rau","year":"2024","unstructured":"Rau B, Lang H, Koenigsrainer A, et al. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial. J Clin Oncol. 2024;42:146\u201356. https:\/\/doi.org\/10.1200\/jco.22.02867.","journal-title":"J Clin Oncol."},{"key":"16142_CR23","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1245\/s10434-017-5838-y","volume":"24","author":"N Ikoma","year":"2017","unstructured":"Ikoma N, Chen HC, Wang X, et al. Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol. 2017;24:2679\u201387. https:\/\/doi.org\/10.1245\/s10434-017-5838-y.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR24","doi-asserted-by":"publisher","first-page":"1094834","DOI":"10.3389\/fphar.2023.1094834","volume":"14","author":"C Jian","year":"2023","unstructured":"Jian C, Mou H, Zhang Y, Fan Q, Ou Y. Survival and complications of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with intra-abdominal malignancies: a meta-analysis of randomized controlled trials. Front Pharmacol. 2023;14:1094834. https:\/\/doi.org\/10.3389\/fphar.2023.1094834.","journal-title":"Front Pharmacol."},{"key":"16142_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.suronc.2019.01.005","volume":"28","author":"T Hotopp","year":"2019","unstructured":"Hotopp T. HIPEC and CRS in peritoneal metastatic gastric cancer: Who really benefits? Surg Oncol. 2019;28:159\u201366. https:\/\/doi.org\/10.1016\/j.suronc.2019.01.005.","journal-title":"Surg Oncol."},{"key":"16142_CR26","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1245\/s10434-019-07450-4","volume":"26","author":"I Manzanedo","year":"2019","unstructured":"Manzanedo I, Pereira F, Rihuete Caro C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish group of peritoneal oncologic surgery (GECOP). Ann Surg Oncol. 2019;26:2615\u201321. https:\/\/doi.org\/10.1245\/s10434-019-07450-4.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR27","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/bjs\/znab200","volume":"108","author":"PE Bonnot","year":"2021","unstructured":"Bonnot PE, Lintis A, Mercier F, et al. Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). Br J Surg. 2021;108:1225\u201335. https:\/\/doi.org\/10.1093\/bjs\/znab200.","journal-title":"Br J Surg."},{"key":"16142_CR28","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","volume":"18","author":"XJ Yang","year":"2011","unstructured":"Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575\u201381. https:\/\/doi.org\/10.1245\/s10434-011-1631-5.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR29","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/1471-2407-12-526","volume":"12","author":"J Sun","year":"2012","unstructured":"Sun J, Song Y, Wang Z, et al. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer. 2012;12:526. https:\/\/doi.org\/10.1186\/1471-2407-12-526.","journal-title":"BMC Cancer."},{"key":"16142_CR30","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1097\/js9.0000000000000457","volume":"109","author":"M Patel","year":"2023","unstructured":"Patel M, Arora A, Mukherjee D, Mukherjee S. Effect of hyperthermic intraperitoneal chemotherapy on survival and recurrence rates in advanced gastric cancer: a systematic review and meta-analysis. Int J Surg. 2023;109:2435\u201350. https:\/\/doi.org\/10.1097\/js9.0000000000000457.","journal-title":"Int J Surg."},{"key":"16142_CR31","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s12094-022-03004-5","volume":"25","author":"Z Chen","year":"2023","unstructured":"Chen Z, Ali M, Kai Z, Wang Y, Wang C. HIPEC with CRS versus cytoreductive surgery (CRS) for the gastric cancer metastasis to peritoneum. Clin Transl Oncol. 2023;25:1011\u20136. https:\/\/doi.org\/10.1007\/s12094-022-03004-5.","journal-title":"Clin Transl Oncol."},{"key":"16142_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.03.030","volume":"79","author":"J Desiderio","year":"2017","unstructured":"Desiderio J, Chao J, Melstrom L, et al. The 30-year experience: a meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer. 2017;79:1\u201314. https:\/\/doi.org\/10.1016\/j.ejca.2017.03.030.","journal-title":"Eur J Cancer."},{"key":"16142_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4251\/wjgo.v2.i2.85","volume":"2","author":"Y Yonemura","year":"2010","unstructured":"Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2:85\u201397. https:\/\/doi.org\/10.4251\/wjgo.v2.i2.85.","journal-title":"World J Gastrointest Oncol."},{"key":"16142_CR34","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejso.2020.10.006","volume":"47","author":"A Brandl","year":"2021","unstructured":"Brandl A, Yonemura Y, Glehen O, Sugarbaker P, Rau B. Long-term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: a multi-institutional cohort from PSOGI. Eur J Surg Oncol. 2021;47:172\u201380. https:\/\/doi.org\/10.1016\/j.ejso.2020.10.006.","journal-title":"Eur J Surg Oncol."},{"key":"16142_CR35","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1245\/s10434-015-5081-3","volume":"23","author":"CS Chia","year":"2016","unstructured":"Chia CS, You B, Decullier E, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol. 2016;23:1971\u20139. https:\/\/doi.org\/10.1245\/s10434-015-5081-3.","journal-title":"Ann Surg Oncol."},{"issue":"Suppl 1","key":"16142_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13193-019-00893-x","volume":"10","author":"Y Yonemura","year":"2019","unstructured":"Yonemura Y, Sako S, Wakama S, et al. History of peritoneal surface malignancy treatment in Japan. Indian J Surg Oncol. 2019;10(Suppl 1):3\u201311. https:\/\/doi.org\/10.1007\/s13193-019-00893-x.","journal-title":"Indian J Surg Oncol."},{"key":"16142_CR37","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/1097-0142(20001101)89:9<1883::aid-cncr3>3.3.co;2-8","volume":"89","author":"CP Theuer","year":"2000","unstructured":"Theuer CP, Kurosaki T, Ziogas A, Butler J, Anton-Culver H. Asian patients with gastric carcinoma in the United States exhibit unique clinical features and superior overall and cancer specific survival rates. Cancer. 2000;89:1883\u201392. https:\/\/doi.org\/10.1002\/1097-0142(20001101)89:9%3c1883::aid-cncr3%3e3.3.co;2-8.","journal-title":"Cancer."},{"key":"16142_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000004261","volume":"95","author":"YW Kim","year":"2016","unstructured":"Kim YW, Joo J, Yoon HM, et al. Different survival outcomes after curative R0-resection for Eastern Asian and European gastric cancer: results from a propensity score-matched analysis comparing a Korean and a German specialized center. Medicine Baltimore. 2016;95:e4261. https:\/\/doi.org\/10.1097\/md.0000000000004261.","journal-title":"Medicine Baltimore."},{"key":"16142_CR39","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1245\/s10434-020-08739-5","volume":"28","author":"B Badgwell","year":"2021","unstructured":"Badgwell B, Ikoma N, Murphy MB, et al. A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and carcinomatosis or positive cytology. Ann Surg Oncol. 2021;28:258\u201364. https:\/\/doi.org\/10.1245\/s10434-020-08739-5.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR40","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00423-021-02137-5","volume":"406","author":"F Rosa","year":"2021","unstructured":"Rosa F, Galiandro F, Ricci R, et al. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center. Langenbecks Arch Surg. 2021;406:1071\u201380. https:\/\/doi.org\/10.1007\/s00423-021-02137-5.","journal-title":"Langenbecks Arch Surg."},{"key":"16142_CR41","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1186\/s12885-020-07601-x","volume":"20","author":"P Yu","year":"2020","unstructured":"Yu P, Ye Z, Dai G, et al. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study. BMC Cancer. 2020;20:1108. https:\/\/doi.org\/10.1186\/s12885-020-07601-x.","journal-title":"BMC Cancer."},{"key":"16142_CR42","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.3390\/cancers15133401","volume":"15","author":"HH Yu","year":"2023","unstructured":"Yu HH, Yonemura Y, Ng HJ, Lee MC, Su BC, Hsieh MC. Benefit of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and bidirectional chemotherapy for patients with gastric cancer with peritoneal carcinomatosis considering cytoreductive surgery. Cancers Basel. 2023;15:3401. https:\/\/doi.org\/10.3390\/cancers15133401.","journal-title":"Cancers Basel."},{"key":"16142_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3978\/j.issn.2078-6891.2015.100","volume":"7","author":"AD Newton","year":"2016","unstructured":"Newton AD, Bartlett EK, Karakousis GC. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality. J Gastrointest Oncol. 2016;7:99\u2013111. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2015.100.","journal-title":"J Gastrointest Oncol."},{"key":"16142_CR44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12094-019-02124-9","volume":"22","author":"PA Cascales-Campos","year":"2020","unstructured":"Cascales-Campos PA, L\u00f3pez-L\u00f3pez V, Torres-Melero J, et al. Survival outcomes in patients aged 75 years and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): multicenter study of the Spanish group of peritoneal cancer surgery (GECOP). Clin Transl Oncol. 2020;22:130\u20136. https:\/\/doi.org\/10.1007\/s12094-019-02124-9.","journal-title":"Clin Transl Oncol."},{"key":"16142_CR45","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1245\/s10434-013-3053-z","volume":"20","author":"KI Votanopoulos","year":"2013","unstructured":"Votanopoulos KI, Newman NA, Russell G, et al. Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol. 2013;20:3497\u2013503. https:\/\/doi.org\/10.1245\/s10434-013-3053-z.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR46","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jss.2022.06.057","volume":"279","author":"S Laks","year":"2022","unstructured":"Laks S, Bilik A, Schtrechman G, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in elderly is safe and effective. J Surg Res. 2022;279:739\u201347. https:\/\/doi.org\/10.1016\/j.jss.2022.06.057.","journal-title":"J Surg Res."},{"key":"16142_CR47","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s13304-020-00966-5","volume":"73","author":"W Ezzedine","year":"2021","unstructured":"Ezzedine W, Mege D, Aubert M, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for resectable peritoneal metastases is feasible in elderly patients. Updates Surg. 2021;73:719\u201330. https:\/\/doi.org\/10.1007\/s13304-020-00966-5.","journal-title":"Updates Surg."},{"key":"16142_CR48","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/jso.22017","volume":"104","author":"RS Gill","year":"2011","unstructured":"Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104:692\u20138. https:\/\/doi.org\/10.1002\/jso.22017.","journal-title":"J Surg Oncol."},{"key":"16142_CR49","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/SLA.0b013e3181a45d86","volume":"249","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900\u20137. https:\/\/doi.org\/10.1097\/SLA.0b013e3181a45d86.","journal-title":"Ann Surg."},{"key":"16142_CR50","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s10120-019-00969-1","volume":"22","author":"B Rau","year":"2019","unstructured":"Rau B, Brandl A, Thuss-Patience P, et al. The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis. Gastric Cancer. 2019;22:1226\u201337. https:\/\/doi.org\/10.1007\/s10120-019-00969-1.","journal-title":"Gastric Cancer."},{"key":"16142_CR51","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1245\/s10434-022-12761-0","volume":"30","author":"BL Green","year":"2023","unstructured":"Green BL, Blumenthaler AN, Gamble LA, et al. Cytoreduction and HIPEC for gastric carcinomatosis: multi-institutional analysis of two phase II clinical trials. Ann Surg Oncol. 2023;30:1852\u201360. https:\/\/doi.org\/10.1245\/s10434-022-12761-0.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-6125-z","volume":"19","author":"MK Beeharry","year":"2019","unstructured":"Beeharry MK, Zhu Z-L, Liu W-T, Yao X-X, Yan M, Zhu Z-G. Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study. BMC Cancer. 2019;19:1\u20139. https:\/\/doi.org\/10.1186\/s12885-019-6125-z.","journal-title":"BMC Cancer."},{"key":"16142_CR53","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.soc.2012.07.005","volume":"21","author":"M Valle","year":"2012","unstructured":"Valle M, Federici O, Garofalo A. Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, and role of laparoscopy in diagnosis, staging, and treatment. Surg Oncol Clin North Am. 2012;21:515\u201331. https:\/\/doi.org\/10.1016\/j.soc.2012.07.005.","journal-title":"Surg Oncol Clin North Am."},{"key":"16142_CR54","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/s0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357. https:\/\/doi.org\/10.1016\/s0140-6736(18)32557-1.","journal-title":"Lancet."},{"key":"16142_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.21037\/tgh.2016.07.03","volume":"1","author":"Z Wu","year":"2016","unstructured":"Wu Z, Li Z, Ji J. Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in advanced gastric cancer. Transl Gastroenterol Hepatol. 2016;1:63. https:\/\/doi.org\/10.21037\/tgh.2016.07.03.","journal-title":"Transl Gastroenterol Hepatol."},{"key":"16142_CR56","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1245\/s10434-019-07492-8","volume":"27","author":"RJ Ellis","year":"2020","unstructured":"Ellis RJ, Schlick CJR, Yang AD, Barber EL, Bilimoria KY, Merkow RP. Utilization and treatment patterns of cytoreduction surgery and intraperitoneal chemotherapy in the United States. Ann Surg Oncol. 2020;27:214\u201321. https:\/\/doi.org\/10.1245\/s10434-019-07492-8.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR57","doi-asserted-by":"publisher","first-page":"20180122","DOI":"10.1515\/pp-2018-0122","volume":"3","author":"NB Shannon","year":"2018","unstructured":"Shannon NB, Tan GHC, Chia CS, Soo KC, Teo MCC. Biphasic learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy:technical competence and refinement of patient selection. Pleura Peritoneum. 2018;3:20180122. https:\/\/doi.org\/10.1515\/pp-2018-0122.","journal-title":"Pleura Peritoneum."},{"key":"16142_CR58","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11605-019-04463-y","volume":"24","author":"TC Lee","year":"2020","unstructured":"Lee TC, Wima K, Sussman JJ, et al. Readmissions after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a U.S. HIPEC collaborative study. J Gastrointest Surg. 2020;24:165\u201376. https:\/\/doi.org\/10.1007\/s11605-019-04463-y.","journal-title":"J Gastrointest Surg."},{"key":"16142_CR59","doi-asserted-by":"publisher","first-page":"6613","DOI":"10.1245\/s10434-021-10414-2","volume":"28","author":"EW Moon","year":"2021","unstructured":"Moon EW, Wong JSM, See AHM, et al. Predicting early and late readmissions following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2021;28:6613\u201324. https:\/\/doi.org\/10.1245\/s10434-021-10414-2.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR60","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.14744\/tjtes.2022.62121","volume":"28","author":"B Mano\u011flu","year":"2022","unstructured":"Mano\u011flu B, S\u00f6kmen S, Bi\u015fgin T, et al. Urgent re-laparotomies in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ulus Travma Acil Cerrahi Derg. 2022;28:1389\u201396. https:\/\/doi.org\/10.14744\/tjtes.2022.62121.","journal-title":"Ulus Travma Acil Cerrahi Derg."},{"key":"16142_CR61","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1245\/s10434-016-5409-7","volume":"23","author":"N Ikoma","year":"2016","unstructured":"Ikoma N, Blum M, Chiang YJ, et al. Yield of staging laparoscopy and lavage cytology for radiologically occult peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol. 2016;23:4332\u20137. https:\/\/doi.org\/10.1245\/s10434-016-5409-7.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.955181","volume":"12","author":"G Guan","year":"2022","unstructured":"Guan G, Li Z, Wang Q, Ying X, Shan F, Li Z. Risk factors associated with peritoneal carcinomatosis of gastric cancer in staging laparoscopy: a systematic review and meta-analysis. Front Oncol. 2022;12:955181. https:\/\/doi.org\/10.3389\/fonc.2022.955181.","journal-title":"Front Oncol."},{"key":"16142_CR63","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/SLA.0b013e3181b0c80e","volume":"250","author":"M Kuramoto","year":"2009","unstructured":"Kuramoto M, Shimada S, Ikeshima S, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg. 2009;250:242\u20136. https:\/\/doi.org\/10.1097\/SLA.0b013e3181b0c80e.","journal-title":"Ann Surg."},{"key":"16142_CR64","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jss.2019.01.039","volume":"238","author":"RM Byrne","year":"2019","unstructured":"Byrne RM, Gilbert EW, Dewey EN, et al. Who undergoes cytoreductive surgery and perioperative intraperitoneal chemotherapy for appendiceal cancer? An analysis of the National Cancer Database. J Surg Res. 2019;238:198\u2013206. https:\/\/doi.org\/10.1016\/j.jss.2019.01.039.","journal-title":"J Surg Res."},{"key":"16142_CR65","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1136\/ijgc-2019-001124","volume":"30","author":"YA Lyons","year":"2020","unstructured":"Lyons YA, Reyes HD, McDonald ME, et al. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy. Int J Gynecol Cancer. 2020;30:845\u201352. https:\/\/doi.org\/10.1136\/ijgc-2019-001124.","journal-title":"Int J Gynecol Cancer."},{"key":"16142_CR66","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1245\/s10434-020-09475-6","volume":"28","author":"Y Berger","year":"2021","unstructured":"Berger Y, Giurcanu M, Vining CC, et al. Cytoreductive surgery for selected patients whose metastatic gastric cancer was treated with systemic chemotherapy. Ann Surg Oncol. 2021;28:4433\u201343. https:\/\/doi.org\/10.1245\/s10434-020-09475-6.","journal-title":"Ann Surg Oncol."},{"key":"16142_CR67","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12885-019-5640-2","volume":"19","author":"WJ Koemans","year":"2019","unstructured":"Koemans WJ, van der Kaaij RT, Boot H, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II). BMC Cancer. 2019;19:420. https:\/\/doi.org\/10.1186\/s12885-019-5640-2.","journal-title":"BMC Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16142-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16142-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16142-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:05:24Z","timestamp":1731071124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16142-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":67,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["16142"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16142-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Schulick is a coinventor of a patent licensed to DynamiCure (managed by the University of Colorado) outside the submitted work. Dr. Pratap received Fellowship funding from the Intuitive Inc Foundation. Dr. Del Chiaro is Co-PI of a Boston Scientific-sponsored study and received a research grant from Haemonetics, Inc. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}